Mesa Laboratories Posts 3.4% Revenue Gain to $249.1M, Q4 AOI Margin at 28.7%
MLAB•Fiscal 2026 revenues reached $249.1 million, up 3.4%, with adjusted operating income rising 11.9% to a 25.5% margin and Q4 AOI margin hitting 28.7% on operating leverage. Sterilization and Disinfection Control led 17.7% Q4 growth while Clinical Genomics, 19% of sales, declined 10.1% as CEO Siddhartha Kadia launches a 100-day review.
1. Fiscal 2026 Financial Results
Fiscal 2026 revenue of $249.1 million rose 3.4% year-over-year, with adjusted operating income excluding unusual items up 11.9% and full-year AOI margin of 25.5%. In the fourth quarter, AOI margin reached 28.7%, reflecting operating leverage from stronger divisions.
2. Division Performance Details
The Sterilization and Disinfection Control division delivered 17.7% organic revenue growth in Q4 and 8.7% for the full year, benefiting from high regulatory switching barriers. Clinical Genomics, representing 19% of sales, posted a 10.1% core organic decline and required a goodwill impairment.
3. Leadership Change and Strategic Review
Dr. Siddhartha Kadia assumed the CEO role on April 13, 2026, initiating a 100-day review of all business units. Insider share purchases by two directors following the leadership transition signal confidence in the company’s strategic direction.
